Tivic Health Systems Inc Cash Flow Conversion Efficiency
Tivic Health Systems Inc cash flow conversion efficiency. Based on the latest financial reports, Tivic Health Systems Inc (TIVC) has a cash flow conversion efficiency ratio of -0.453x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.01 Million) by net assets ($11.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tivic Health Systems Inc (2019–2025)
Cash flow conversion efficiency of Tivic Health Systems Inc from 2019 to 2025. This chart illustrates how Tivic Health Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Tivic Health Systems Inc (TIVC) stock price for real-time trading data and today's change.
Tivic Health Systems Inc Cash Flow Conversion Ratio Explained
Tivic Health Systems Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tivic Health Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tivic Health Systems Inc ranked by their cash flow conversion efficiency. Also see market cap of Tivic Health Systems Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
URU METALS LTD
F:NVRA
|
N/A |
|
ModuLink Inc.
NASDAQ:MDLK
|
-1.967x |
|
Reinhold Europe AB
WAR:RHD
|
0.023x |
|
Beyond Air Inc
NASDAQ:XAIR
|
-0.796x |
|
Macfarlane Group PLC
LSE:MACF
|
0.103x |
|
Yangaroo Inc
V:YOO
|
0.540x |
|
Alturas Minerals Corp
V:ALT
|
0.011x |
|
Lazydays Holdings Inc
NASDAQ:GORV
|
0.889x |
Annual Cash Flow Conversion Efficiency for Tivic Health Systems Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tivic Health Systems Inc from 2019 to 2025. Review TIVC financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.80 Million | $-7.00 Million | -0.417x | +81.55% |
| 2024-12-31 | $2.54 Million | $-5.72 Million | -2.258x | +5.01% |
| 2023-12-31 | $3.58 Million | $-8.51 Million | -2.377x | +3.24% |
| 2022-12-31 | $3.63 Million | $-8.92 Million | -2.457x | -481.07% |
| 2021-12-31 | $13.27 Million | $-5.61 Million | -0.423x | -116.44% |
| 2020-12-31 | $-1.18 Million | $-3.03 Million | 2.572x | +266.15% |
| 2019-12-31 | $2.37 Million | $-3.67 Million | -1.548x | -- |
About Tivic Health Systems Inc
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offe… Read more